摘要
目的探讨化疗剂量强度对晚期乳腺癌近期疗效的影响。方法对63例晚期乳腺癌给予不同剂量强度的紫杉醇联合表阿霉素化疗,紫杉醇按标准剂量每3周175mg/m2,剂量强度为58.3mg/m2;表阿霉素按标准剂量每3周60mg/m2,剂量强度为20mg/m2,评估其客观疗效及毒副作用。结果63例晚期乳腺癌患者总有效率为49.2%,相对剂量强度为>1.0、1.0~0.8、<0.8,三者的有效率分别为76.5%、53.1%、7.1%,有显著性差异(P<0.05)。结论晚期乳腺癌对化疗药物比较敏感,标准剂量强度可以产生较好的化疗效果,且毒副作用可耐受。
Objective To evaluate the influence of dose intensity to the response of advanced breast cancer chemotherapy. Methods Sixty-three patients with advanced breast cancer patients received paclitaxel and epirubicin chemotherapy with different dose intensities. The standard dose intensity of paclitaxel was defined as 58.3mg/m^2, the dose was 175mg/m^2 given every three weeks. The standard dose intensity of epirubicin was defined as 20 mg/m^2 ,the dose was 60mg/m^2 given every three weeks. Efficacy and toxicity was evaluated. Results The overall response rate of this group of advanced breast cancer patients was 49.2%. When the relative dose intensity was 〉 1.0,1.0 -0.8, 〈 0. 8, the response rates were 76.5% ,53.1% ,7.1%, respectively. The difference among the three groups was significant （ P 〈 0.05 ）. Conclusion Advanced breast cancer is relatively sensitive to the chemotherapy. The standard dose intensity of paclitaxel and epirubicin chemotherapy is effective and well tolerated.
出处
《实用癌症杂志》
2007年第2期194-195,200,共3页
The Practical Journal of Cancer
关键词
乳腺肿瘤
化疗药物剂量强度
化疗效果
Breast neoplasms
Dose intensity of chemotherapy
Response rate of chemotherapy
